PMID: 12773449May 30, 2003Paper

Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series

Human Reproduction
Hisao AndoShigehiko Mizutani

Abstract

Ovarian hyperstimulation syndrome (OHSS) is an important and dangerous aspect of assisted reproduction techniques. Although elective cryopreservation of all embryos can prevent pregnancy-induced late OHSS, it cannot prevent early OHSS, which is induced by hCG administration. We undertook this trial to assess the efficacy with which the combined oral administration of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor blocker (ARB) could prevent early OHSS in IVF patients at very high risk for this syndrome. Four women, who had serum estradiol concentration > or =8000 pg/ml on the day of hCG injection, were treated with the combination of the ACEI alacepril and the ARB candesartan cilexetil for 8 days starting the day after oocyte retrieval. Embryos were cryopreserved and embryo transfer was postponed until later cycles. Despite the extremely enlarged ovaries, no ascites was accumulated in any of the cases. Haematocrit (34.1 +/- 1.0) and serum albumin concentration (4.1 +/- 0.2 g/dl) were normal throughout the treatment period. These patients showed elevated plasma renin and angiotensin II concentration before the treatment. The dual renin-angiotensin blockade therapy used here would be worth exploring fu...Continue Reading

Citations

Feb 4, 2010·Journal of Assisted Reproduction and Genetics·Tatsuo NakaharaHisao Ando
Feb 9, 2010·Journal of Assisted Reproduction and Genetics·Carolina O NastriWellington P Martins
May 28, 2013·Human Fertility : Journal of the British Fertility Society·Bee Kang Tan, Raj Mathur
Sep 10, 2014·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·G N ChistyakovaO V Chermyaninova
Mar 1, 2006·Expert Opinion on Biological Therapy·Kazuhiko InoFumitaka Kikkawa
Aug 19, 2015·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Michele KwikClare Boothroyd
Sep 24, 2016·Analytical Cellular Pathology (Amsterdam)·Katrin KreienbringElena I Braicu
May 17, 2006·Journal of Cardiovascular Pharmacology and Therapeutics·Sofia G TsouliMoses S Elisaf
Nov 9, 2016·Reproductive Sciences·Angela PalumboFrederick Naftolin
Mar 2, 2005·Obstetrics and Gynecology·Akira IwaseShigehiko Mizutani
Jun 9, 2016·Current Opinion in Obstetrics & Gynecology·Michele Kwik, Elizabeth Maxwell
Jul 2, 2020·International Journal of Molecular Sciences·Kamila Domińska
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takayasu SuganumaFumitaka Kikkawa
Jul 17, 2021·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·Usama M FoudaHala Nabil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.